Successful Utilization of the GLP-1 Receptor Agonist Semaglutide in Treating the Manifestations of Recalcitrant Celiac Disease

A refractory case of abdominal swelling (pseudoascites) due to celiac disease which did not respond to monotherapy with a gluten-free diet and for which treatment with traditional immunosuppressives was refused is described. Based on reports of the anti-inflammatory actions of the GLP-1 receptor agonist, semaglutide, weekly subcutaneous injections of semaglutide were added to the gluten-free diet with rapid and obvious success. Semaglutide and perhaps other GLP-1 receptor agonists should be considered for use as a largely safe anti-inflammatory drug in other autoimmunopathies and inflammatory states.

Authors

Publication Details

Journal
Archives of Clinical and Biomedical Research
Published
2025-01-01
DOI
https://doi.org/10.26502/acbr.50170480
Primary Topic
Celiac Disease Research and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Successful Utilization of the GLP-1 Receptor Agonist Semaglutide in Treating the Manifestations of Recalcitrant Celiac Disease

David S.H. Bell, Terri Jerkins
Archives of Clinical and Biomedical Research
Celiac Disease Research and Management
article

Successful Utilization of the GLP-1 Receptor Agonist Semaglutide in Treating the Manifestations of Recalcitrant Celiac Disease

David S.H. Bell, Terri Jerkins
article en

Abstract

A refractory case of abdominal swelling (pseudoascites) due to celiac disease which did not respond to monotherapy with a gluten-free diet and for which treatment with traditional immunosuppressives was refused is described. Based on reports of the anti-inflammatory actions of the GLP-1 receptor agonist, semaglutide, weekly subcutaneous injections of semaglutide were added to the gluten-free diet with rapid and obvious success. Semaglutide and perhaps other GLP-1 receptor agonists should be considered for use as a largely safe anti-inflammatory drug in other autoimmunopathies and inflammatory states.

Archives of Clinical and Biomedical ResearchVol. 9(5)
Openalex Percentile: Top 60%
Celiac Disease Research and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.